AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4800
- Registration Number
- NCT06307652
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT06304961
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 360
- Registration Number
- NCT06299826
- Locations
- 🇸🇰
Research Site, Kosice, Slovakia
A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT06297668
- Locations
- 🇩🇪
Research Site, Berlin, Germany
REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma
Terminated
- Conditions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT06299306
- Locations
- 🇩🇪
Research Site, Weissenburg, Germany
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT06283966
- Locations
- 🇬🇧
Research Site, Witney, United Kingdom
PROPE Severe Asthma Study in Egypt
Recruiting
- Conditions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06283290
- Locations
- 🇪🇬
Research Site, Cairo, Egypt
C.Difficile Observational Study
Recruiting
- Conditions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06277999
- Locations
- 🇺🇸
Research Site, Charlottesville, Virginia, United States
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT06271837
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 73
- Registration Number
- NCT06269484
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath